SOURCE: Pharm Control Ltd.

January 23, 2007 09:00 ET

Pharm Control Ltd. Now Trading on the OTC

NEW YORK, NY -- (MARKET WIRE) -- January 23, 2007 -- Pharm Control Ltd. is pleased to announce that the company now trades on the OTC pink sheets under the symbol PMCL (PINKSHEETS: PMCL).

The company is focused on the development of natural, no side effect supplements to cure diseases such as Diabetes, high blood pressure and high cholesterol related sicknesses, digestive disorders, liver and kidney diseases.

The first product in the development pipeline is Control-24, a natural product that is focused on the Diabetes and pre-Diabetes market.

About Pharm Control Ltd.

Pharm Control Ltd. is a leading medicine Research and Development company that is devoted to developing medicines that allow patients to live longer, healthier, and more productive lives. The Company's founders have invested over 10 years of research discovering and developing new and effective non-synthetic medicines to fight disorders and sickness in the modern world.

Safe Harbor Statement

The preceding includes forward-looking statements, which involve known and unknown risks, and uncertainties, which may cause the company's actual results in future periods to differ materially from forecasted results. Any forward-looking statements above are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially due to a variety of factors, including, without limitation, competition, intellectual property rights, litigation, needs of liquidity, and other risks detailed from time to time in the company's reports filed with the SEC. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, but not limited to, continued acceptance of the company's products and services, competition, new products and technological changes, as well as any and all "other risks" associated with business.

Contact Information


    Pharm Control Ltd.
    Eugene Kron
    Vice President
    Email: Email Contact